Approved Drugs for Endocrinology
Cycloset, bromocriptine mesylate; VeroScience;
For the treatment of type 2 diabetes mellitus, Approved May 2009
Onglyza (saxagliptin); Bristol-Myers Squibb;
For the treatment of type 2 diabetes mellitus, Approved July 2009
Accretropin (somatropin rDNA Original); Cangene Corp;
For the treatment of growth failure in pediatrics, Approved January 2008
Welchol (colesevelam hydrochloride); Daiichi Sankyo;
For the improvement of glycemic control in adults with type 2 diabetes mellitus, Approved January 2008
Evamist (estradiol); Vivus;
For the treatment of moderate to severe vasomotor symptoms due to menopause, Approved July 2007
Fenofibrate; LifeCycle Pharma;
For the treatment of hyperlipidemia, dyslipidemia and hypertriglyceridemia, Approved August 2007
Somatuline Depot (lanreotide acetate); Beaufour Ipsen;
For the treatment of acromegaly, Approved August 2007
Supprelin LA (histrelin acetate); Indevus Pharmaceuticals;
For the treatment of central precocious puberty, Approved May 2007
Elestrin (estradiol gel); BioSante;
For the treatment of vasomotor symptoms associated with menopause, Approved December 2006
Januvia(sitagliptin phosphate); Merck;
For the treatment of type II diabetes, Approved October 2006
ACTOplus met (pioglitazone hydrochloride and metformin hydrochloride); Takeda;
For the treatment of type 2 diabetes, Approved August of 2005
Byetta (exenatide); Amylin/Eli Lilly;
For the adjunctive treatment of Type 2 diabetes mellitus, Approved April, 2005
Increlex (mecasermin); Tercica;
For the treatment of growth failure due to Primary IGFD, Approved August 2005
Symlin (pramlintide); Amylin Pharmaceuticals;
For the treatment of type I and type II diabetes, Approved March 2005
Aldurazyme (laronidase); Genzyme;
For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65, Approved May 2003
Fabrazyme (agalsidase beta); Genzyme;
For the treatment of Fabry disease in adult patients, Approved April 2003
Somavert (pegvisomant); Pharmacia;
Injectable formulation for the treatment of acromegaly, Approved March 2003
Avandamet (rosiglitazone maleate and metformin HCl); GlaxoSmithKline;
For improvement of glycemic control in type 2 diabetes patients, Approved October 2002
Benicar; Daiichi Sankyo;
Oral tablet for the treatment of hypertension, Approved April 2002
Bravelle (urofollitropin for injection, purified); Ferring Pharmaceuticals;
Human-derived follicle-stimulating hormone (hFSH) for use in ovulation induction for the treatment of infertility., Approved May 2002
Forteo (teriparatide); Eli Lilly;
For the treatment of Osteoporosis in postmenopausal women and men who are at high risk for a fracture., December 2002
Levo-T (levothyroxine sodium); Mova Pharmaceutical;
Indicated for the treatment of hypothyroidism and the suppression of thyroid stimulating hormone, Approved March 2002
Metaglip (glipizide/metformin HCl); Bristol-Myers Squibb;
Oral tablets for the treatment of type 2 diabetes., Approved October 2002
Novothyrox (levothyroxine sodium); Genpharm;
For the treatment of hypothyroidism and suppression of thyroid-stimulating hormone, Approved May 2002
Synthroid (levothyroxine sodium); Abbott Laboratories;
For replacement or supplemental therapy for hypothyroidism and pituitary thyroid stimulating hormone suppression, Approved July 2002
Testim; Auxilium Pharmaceuticals;
External cream for the treatment of male hormone deficiency., Approved October 2002
Campath; Berlex Laboratories;
Injectable treatment of B-cell chronic lymphocytic leukemia, Approved May 2001
Diovan (valsartan); Novartis;
Oral capsules and tablets for the treatment of hypertension, Approved January 1997 (capsules); July 2001 (tablets)
Femara (letrozole); Novartis;
First-line treatment of postmenopausal women with locally advanced or metastatic breast cancer, Approved January 2001
Genotropin (somatropin) injection; Pharmacia;
For the treatment of growth failure in children who were born small for gestational age (SGA), Approved July 2001
Gleevec (imatinib mesylate); Novartis;
Oral therapy for the treatment of chronic myeloid leukemia, Approved May 2001
Levoxyl; Jones Pharma;
Oral therapy for the treatment of hypothyroidism and suppression of thyroid-stimulating hormone (TSH), Approved May 2001
Natrecor (nesiritide); Scios;
For the treatment of patients with acutely decompensated congestive heart failure, Approved August 2001
Novolog Mix 70/30; Novo Nordisk;
Subcutaneous injection for the control of hyperglycemia, associated with type 1 and 2 diabetes, Approved November 2001
Prozac Weekly (fluoxetine HCl); Eli Lilly;
For the treatment of depression, Approved February 2001
Remeron SolTab (mirtazapine); Organon;
Orally disintegrating tablet for the treatment of depression, Approved January 2001
Remicade (infliximab); Centocor;
For inhibiting the progression of structural damage in patients with rheumatoid arthritis, Approved January 2001
Trelstar LA (triptorelin pamoate); Debiopharm;
Intramuscular injection for the treatment of advanced stage prostate cancer, Approved June 2001
Yasmin (drospirenone/ethinyl estradiol); Berlex Laboratories;
Oral contraceptive, Approved May 2001
Zometa (zoledronic acid); Novartis;
For the treatment of hypercalcemia of malignancy, Approved August 2001
Activella (Estradiol/Norethindrone Acetate) Tablets; Novo Nordisk;
Combination hormone replacement therapy for the prevention of osteoporosis and other symptoms associated w/postmenopause, Approved April 2000
AndroGel testosterone gel; Unimed Pharmaceuticals;
For testosterone replacement therapy in males with testosterone deficiency, Approved February 2000
Atacand (candesartan cilexetil); AstraZeneca;
For the treatment of hypertension, Approved September 2000
Cetrotide; Asta Medica;
For the prevention of premature ovulation in women undergoing controlled ovarian stimulation, Approved August 2000
Diltiazem HCL, Extended-Release Capsules; Biovail Laboratories;
For the reduction of high blood pressure, Approved January 2000
Hectorol (Doxercalciferol) Injection; Bone Care International;
To reduce iPTH levels in management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis, Approved April 2000
Lantus (insulin glargine [rDNA origin] injection); Sanofi-aventis;
For adults and children w/Type 1 diabetes, or adults w/Type 2 diabetes requiring basal insulin to control hyperglycemia, Approved April 2000
Lantus (insulin glargine [rDNA origin] injection); Sanofi-aventis;
For the treatment of type I and type II diabetes mellitus in adults and pediatrics, Approved April 2000
Lescol XL (fluvastatin sodium) tablet, extended release; Novartis;
For the use as an adjunct to diet to reduce elevated total cholesterol, Approved October 2000
Micardis HCT (telmisartan and hydrochlorothiazide); Boehringer Ingelheim;
For the treatment of hypertension, Approved November 2000
Mirena (levonorgestrel-releasing intrauterine system); Berlex Laboratories;
Hormone-releasing system for intrauterine contraception, Approved December 2000
NovoLog (insulin aspart); Novo Nordisk;
An insulin analogue for the treatment of diabetes mellitus., Approved June 2000
Ovidrel (gonadotropin, chorionic human recombinant); Serono Laboratories;
For the induction of final follicular maturation and early luteinization in infertile women, Approved September 2000
Trelstar Depot (triptorelin pamoate); Debio Rechereche Pharmaceutique, Target Research Associates;
For the palliative treatment of advanced prostate cancer, Approved June 2000
Viadur (leuprolide acetate implant); Alza;
For pain relief in men with advanced prostate cancer, Approved March 2000
Vivelle (estradiol transdermal system); Novartis;
For the prevention of postmenopausal osteoporosis, Approved August 2000
ACTOS; Takeda;
Treatment for type II diabetes, Approved July 1999
Aggrenox; Boehringer Ingelheim;
Aggrenox (aspirin/extended-release dipyridamole) 25mg/200mg capules for the prevention of recurrence of stroke, Approved November 1999
Aromasin Tablets; Pharmacia & Upjohn;
Exemestane Tablets, 25 mg, October 21, 1999
Avandia (rosiglitazone maleate); SmithKline Beecham;
Treatment for type II diabetes mellitus, Approved June 1999
Cernevit; Baxter Healthcare;
For the treatment of vitamin deficiency, Approved April 1999.
Climara; Berlex Laboratories;
For the prevention of postmenopausal osteoporosis (loss of bone mass), Approved June 1999
Doxil (doxorubicin HCl liposome injection); Alza;
Treatment for ovarian cancer that is refractory to other first-line therapies, Approved June 1999
Ellence; Pharmacia & Upjohn;
epirubicin hydrochloride, Approved September 1999
Ethyol (amifostine); U.S. Bioscience, Alza;
Treatment for xerostomia (dry mouth) due to radiation, Approved June 1999
Evista (raloxifene hydrochloride); Eli Lilly;
Osteoporosis treatment, Approved September 1999
Femhrt Tablets; Parke-Davis;
Norethindrone acetate (1mg) and ethinyl estradiol tablets (5mcg), October 15, 1999
Ortho-Prefest; Ortho-McNeil Pharmaceutical, R.W. Johnson;
17 beta estradiol/17 beta estradiol norgestimate tablets, October 22, 1999
Xenical/Orlistat Capsules; Roche;
Treatment for obesity management, Approved April 1999
Actonel; Procter & Gamble, Hoechst Marion Roussel;
Treatment for Paget's Disease, Approved April 1998
Arava; Hoechst Marion Roussel;
Treatment for Rheumatoid Arthritis, Approved September 1998
Atacand (candesartan cilexetil); Astra Merck;
Treatment for hypertension, Approved June 1998
Atacand (candesartan cilexetil); Astra Merck;
Treatment for hypertension, Approved June 1998
Celexa; Forest Laboratories;
Treatment for depression, Approved July 1998
CellCept; Roche;
Treatment for the prevention of organ rejection inpatients undergoing heart transplants, Approved February 1998
Clomipramine hydrochloride; Mylan Laboratories;
Generic equivalent of Anafranil, Approved April 1998
Diovan HCT (valsartan); Novartis;
Treatment for hypertension, Approved March 1998
Esclim; Fournier Research;
Treatment for symptoms associated to Menopause, Approved August 1998
Estratab (.3 mg ); Solvay Pharmaceuticals;
Treatment for the prevention of osteoporosis, Approved March 1998
Glucagon; Eli Lilly;
Treatment for severe hypoglycemia associated with diabetes., Approved October 1998
Glucagon; Eli Lilly;
Treatment for severe Hypoglycemia, Approved September 1998
Glyburide Tablets; Mylan Laboratories;
Treatment for Diabetes Mellitus (Type II), Approved July 1998.
Herceptin; Genentech;
Treatment for metastatic breast cancer, Approved October 1998
Inform HER-2/neu breast cancer test; Oncor;
Treatment for breast cancer prediction, Approved January 1998
Marplan Tablets; Roche;
Treatment of Depression, Approved August 1998
Mircette; Organon;
Oral contraceptive, Approved April 1998
Prempro; Wyeth;
Treatment for hormone replacement therapy, Approved January 1998
Prometrium; Schering-Plough;
Treatment for Endometrial Hyperplasia, Approved December 1998
Proscar; Merck;
Treatment for complication relating to benign prostatic hyperplasia (BPH), Approved April 1998
Simulect; Novartis;
Treatment for acute organ transplant rejection, Approved May 1998
Xeloda; Roche;
Treatment for advanced breast cancer tumors, Approved April 1998
Zemplar; Abbott Laboratories;
Treatment of secondary hyperparathyroidism associated with chronic renal failure, Approved April 1998
Baycol (cerivastatin sodium); Bayer;
Treatment for high cholesterol, Approved June 1997; withdrawn 8/8/01
Captopril and hydrochlorotiazide; Mylan Laboratories;
Generic equivalent of Capozide, Approved (tentatively) May 20, 1997
Captopril and hydrochlorotiazide; Mylan Laboratories;
Treatment for hypertension, Approved May 1997
Corlopam; Neurex;
Treatment for severe high blood pressure, Approved September 1997
Crinone 8% (progesterone gel); Wyeth;
Treatment for infertile women with pregestone deficiency, Approved May 1997
Diovan (valsartan); Ciba Pharmaceuticals;
Treatment for hypertension, Approved January 1997
Dostinex Tablets (cabergoline tablets); Pharmacia & Upjohn;
Treatment of hyperprolactinemic disorders, Approved January 1997
DynaCirc CR; Novartis;
Treatment for hypertension, Approved February 1997
Effexor XR (venlafaxin HCI); Wyeth;
Treatment of depression, Approved October 1997
Estradiol tablets; Barr Laboratories;
Generic equivalent of Estrace, Approved October 1997
Estradiol tablets; Duramed Pharmaceuticals;
Generic equivalent of Estrace tablets, Approved December 1997
Estrostep (norethindrone acetate and ethinyl estradiol); Warner-Lambert;
Treatment for oral contraception, Approved March 1997
Etodolac; Royce Laboratories;
Generic equivalent of Lodine, Approved April 1997
Evista (raloxifene hydrochloride); Eli Lilly;
Treatment for the prevention of osteoporosis, Approved December 1997
Femara (letrozole); Novartis;
Treatment for breast cancer, Approved July 1997
Follistim (TM) (follitropin beta for injection); Organon;
Treatment for infertility, Approved September 1997
Genotropin (somatropin) lyophilized powder; Pharmacia & Upjohn;
Treatment for growth hormone deficiency in adults, Approved November 1997
Geref (sermorelin acetate for injection); Serono Laboratories;
Treatment for pedicatric growth disorder, Approved October 1997
Gliadel Wafer (polifeprosan 20 with carmustine implant); Rhone-Poulenc Rorer, Guilford Pharmaceuticals;
Treatment for brain cancer, Approved February 1997
Glipizide Tablets; Duramed Pharmaceuticals;
Treatment for diabetes, Approved September 1997
Glyburide Tablets; Roche;
Treatment for blood-glucose lowering, Approved December 1997
Glyburide Tablets; Mova Pharmaceutical;
Generic version of Glynase PresTab, Approved December 1997
Gonal-F (follitropin alfa for injection); Serono Laboratories;
Treatment for infertility, Approved September 1997
Lescol (fluvastatin sodium); Novartis;
Treatment for coronary atherosclerosis, Approved September 1997
Lexxel (enalapril maleate-felodipine ER); Astra Merck;
Treatment for hypertension, Approved January 1997
MERIDIA; Knoll Pharmaceutical;
Treatment for obesity, Approved November 1997
Microzide (hydrochlorothiazide); Watson Pharmaceuticals;
Treatment for mild-to moderate hypertension, Approved January 1997
Norditropin (somatropin (rDNA origin) for injection); Novo Nordisk;
Treatment of children who have growth failure, Approved February 1997
Nutropin (somatropin-rDNA origin); Genentech;
Treatment for growth hormone deficiency, Approved December 1997
Pindolol; Teva Pharmaceutical;
Generic equivalent of Visken, Approved April 1997
Plavix (clopidogrel bisulfate); Sanofi-aventis, Bristol-Myers Squibb;
Treatment for cardiac atherosclerotic events, Approved November 1997
Posicor; Roche;
Treatment for hypertension and chronic stable angina pectoris, Approved June 1997
Prandin; Novo Nordisk;
Treatment for Type II diabetes, Approved December 1997
Prograf; Fujisawa Healthcare;
Treatment for the prevention of kidney transplant rejection, Approved April 1997
REGRANEX (becaplermin) Gel; R.W. Johnson;
Treatment for diabetic foot ulcers, Approved December 1997
REPRONEX(menotropins for injection, USP); Ferring Pharmaceuticals;
Generic equivalent of Pergonal, Approved February 1997
Skelid (tiludronate disodium); Sanofi-aventis;
Treatment for Paget’s disease of bone, Approved March 1997
Testoderm TTS CIII; Alza;
Treatment for testosterone deficiency, Approved December 1997
Teveten (eprosartan mesylate); SmithKline Beecham;
Treatment for hypertension, Approved December 1997
Trazadone 150mg; Teva Pharmaceutical;
Generic equivalent of Desyrel 7, Approved May 1997
Trivora-21 and Trivora-28; Watson Pharmaceuticals;
Generic equivalents of levonorgestrel and ethinyl estradiol, Approved December 1997
Verapamil; IVAX;
Generic equivalent of Knoll's Isoptin SR and Searle's Calan SR, Approved December 1997
Zenapax; Roche;
Treatment to prevent rejection of kidney transplants, Approved December 1997
Zerit (stavudine); Bristol-Myers Squibb;
Treatment for infants and children infected with HIV, Approved January 1997
Aredia (pamidronate disodium for injection); Chiron;
Treatment for osteolytic bone metastases of breast cancer, Approved August 1996
Arimidex (anastrozole); AstraZeneca;
Treatment for advanced breast cancer in postmenopausal women, Approved January 1996
Azulfidine EN-tabs Tablets (sulfasalazine delayed release tablets, USP); Pharmacia & Upjohn;
Treatment for rheumatoid arthritis, Approved October 1996
Campostar; Pharmacia & Upjohn;
Treatment for metastatic colorectal cancer, Approved June 1996
CEA-Scan; Immunomedics;
Diagnostic imaging product for colorectal cancer, Approved April 1996
Confide; Johnson & Johnson;
HIV testing and counseling service, Approved May 1996
Covera-HS (verapamil); G.D. Searle, Alza;
Treatment for hypertension and angina, Approved January 1996
Desmopressin Acetate (DDAVP); Rhone Poulenc Rorer;
Treatment for central diabetes insipidus, Approved February 1996
Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection); Orphan Medical;
Treatment of meningeal leukemia or lymphocytic lymphoma, Approved October 1996
Estrostep (norethindrone acetate and ethinyl estradiol); Parke-Davis;
Treatment for birth control, Approved October 1996
Eulexin (flutamide); Schering-Plough;
Treatment for prostate cancer, Approved June 1996
FemPatch; Parke-Davis;
Treatment for menopausal symptoms, Approved December 1996
Fertinex (urofollitropin for injection, purified); Serono Laboratories;
Treatment for patients undergoing infertility treatments, Approved September 1996
Gemzar (gemcitabine HCL); Eli Lilly;
Treatment for pancreatic cancer, Approved May 1996
Glyset (miglitol); Bayer;
Treatment for Type II (non-insulin-dependent) diabetes mellitus, Approved December 1996
Humalog (insulin lispro); Eli Lilly;
Treatment for type I and type II diabetes, Approved June 1996
Humatrope (somatropin [rDNA origin] for injection); Eli Lilly;
Treatment for Somatropin Deficiency Syndrome, Approved August 1996
Hycamtin (topotecan hydrochloride); SmithKline Beecham;
Treatment for metastatic ovarian cancer, Approved May 1996
Lithobid (Lithium Carbonate); Solvay Pharmaceuticals;
Treatment for manic depression, Approved January 1996
Lodine (etodolac); Wyeth;
Treatment for rheumatoid arthritis, Approved July 1996
Lupron Depot (leuprolide acetate for depot suspension); Abbott Laboratories;
Treatment for advanced prostate cancer, Approved January 1996
Mavik (trandolapril); Knoll Pharmaceutical;
Treatment for hypertension, Approved May 1996
Naprelan (naproxen sodium); Elan Pharmaceuticals, Wyeth;
Treatment for osteoarthritis and rheumatoid arthritis, Approved January 1996
Nascobal Gel (Cyanocobalamin, USP); Questcor Pharmaceuticals;
Treatment for vitamin B-12 deficiency, Approved November 1996
Nutropin (somatropin-rDNA origin); Genentech;
Treatment that consists of recombinant growth hormone product, Approved January 1996
OxyContin (oxycodone HCl controlled-release); Purdue Pharma;
Treatment for pain associated with musculoskeletal conditions, Approved May 1996
Pravachol (pravastatin sodium); Bristol-Myers Squibb;
Treatment for cholesterol-lowering, Approved July 1996
Redux (dexfenfluramine hydrochloride); Wyeth;
Treatment for obesity, Approved May 1996
Remeron (Mirtazapine); Organon;
Treatment for depression, Approved June 1996
Saizen; Ares-Serono;
Treatment for growth hormone deficiency and Turner Syndrome, Approved May 1996
Taxotere (Docetaxel); Rhone Poulenc Rorer;
Treatment for locally advanced or metastatic breast cancer, Approved May 1996
Teczem (enalapril maleate/diltiazem malate); Hoechst Marion Roussel;
Treatment for hypertension, Approved October 1996
Tiazac (diltiazem hydrochloride); Forest Laboratories;
Treatment for hypertension, Approved February 1996
Vivelle (estradiol transdermal system); Ciba Pharmaceuticals;
Treatment for moderate and severe vasomotor menopausal symptoms, Approved March 1996
Zoladex (10.8 mg goserelin acetate implant); AstraZeneca;
Treatment for advanced prostate cancer, Approved January 1996
Amaryl (Glimepiride); Hoechst Marion Roussel;
Treatment for type II diabetes, Approved December 1995
Androderm (Testosterone Transdermal System); TheraTech;
Treatment for primary and secondary hypogonadism, Approved on September 29, 1995
Epivir (lamivudine); GlaxoSmithKline;
Treatment used in combination with AZT for AIDS/HIV infection, Approved on November 17, 1995
Ethyol (amifostine); Alza;
Treatment to reduce renal toxicity associated with chemotherapy in subjects with advanced ovarian cancer, Approved December 8, 1995
Fosamax (alendronate sodium); Merck;
Treatment for osteoporosis in women after menopause and Paget's Disease of Bone, Approved on September 29, 1995
Invirase (saquinavir); Roche;
Treatment for HIV/AIDS, Approved on December 7, 1995
Leukine (sargramostim); Immunex;
Treatment for mobilizing peripheral blood progenitor cells for use after transplantation., Approved on November 24, 1995
Miacalcin (calcitonin-salmon) Nasal Spray; Sandoz Pharmaceuticals;
Treatment for post-menopausal osteoporosis, Approved on August 17, 1995
Precose (acarbose); Bayer;
Treatment for non-insulin-dependent diabetes mellitus, Approved September 6, 1995
Prempro & Premphase (conjugated estrogens/medroxyprogesterone acetate tablets); Wyeth;
Treatment for postmenopausal hormone replacement, postmenopausal osteoporosis, Approved November 1995
Prinivil or Zestril (Lisinopril); Merck, Zeneca;
Treatment for hypertension, heart failure, and acute myocardial infarction, Approved November 24, 1995
Western blot confirmatory device; Epitope;
Confirmatory test for HIV, Approved in December 1995
